Latest Alnylam Pharmaceuticals (ALNY) Headlines
Can Alexion Pharmaceuticals Continue to Deliver?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Wed Mar 12, 1:30PM CDT
Successful biotechs are generally expected to reinvest their profits into the development of broad pipelines, but Alexion is following a somewhat different path. While I do not mean to give short shrift to this company's pipeline development...
Marketing Authorization Applications, Quarterly Dividends, Publication of Clinical Trial Data, Acquisitions, and Financial Results - Analyst Notes on Regeneron, Amgen, Sangamo, Alnylam, and Agios
PR Newswire - Tue Mar 11, 8:08AM CDT
Today, Analysts Review released its analysts' notes regarding Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Amgen, Inc. (NASDAQ: AMGN), Sangamo BioSciences, Inc. (NASDAQ: SGMO), Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), and Agios Pharmaceuticals, Inc. (NASDAQ: AGIO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Arrowhead Research Surges as It Advances Its Drug for Hepatitis B into Phase 2
Todd Campbell, The Motley Fool - Motley Fool - Fri Mar 07, 1:30PM CST
Shares in speculative biotechnology company Arrowhead , which was one of 2013's best performing biotechs , jumped nearly 25% following news its lead compound is heading into phase 2 trials. The company won approval from Hong Kong regulators to...
Alnylam Pharmaceuticals acquires Sirna Therapeutics from Merck
M2 - Fri Mar 07, 5:06AM CST
RNAi therapeutics company Alnylam Pharmaceuticals (NasdaqGS:ALNY), based in the US, revealed on Thursday the completion of the acquisition of Sirna Therapeutics in a stock purchase agreement.
Alnylam to Webcast Presentation at Barclays Global Healthcare Conference
Business Wire - Thu Mar 06, 3:00PM CST
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the Barclays Global Healthcare Conference on Thursday, March 13, 2014 at 10:45 a.m. ET at the Loews Miami Hotel in Miami, Florida.
Alnylam Announces Closing of Previously Announced Acquisition of Merck's Sirna Therapeutics Subsidiary
Business Wire - Thu Mar 06, 7:01AM CST
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the previously announced acquisition of Merck's wholly owned subsidiary Sirna Therapeutics, Inc. ("Sirna Therapeutics" or "Sirna") has closed, following the expiration of the Hart-Scott-Rodino waiting period. On January 10, 2014, Alnylam entered into a stock purchase agreement with Merck pursuant to which Alnylam agreed to purchase from Merck all of Merck's rights, title, and interest in and to all of the outstanding shares of common stock of Sirna Therapeutics. In consideration for the Sirna common stock, Alnylam paid Merck $25.0 million in cash. In addition, Alnylam agreed to issue to Merck 2,520,044 shares of Alnylam common stock, having a value of $150.0 million as calculated under the terms of the stock purchase agreement on the date of execution, and representing an approximately 3% ownership position in Alnylam's outstanding common stock. Alnylam issued 85% of the shares at the closing and will issue the remainder of shares upon the completion of certain technology transfer activities pursuant to the terms of the stock purchase agreement.
Are These Biotechs Part of Your Portfolio? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 9:52AM CST
The biotech sector holds great promise and is expected to grow at a rapid pace.
Alnylam Announces Closing of Previously Announced Alliance with Genzyme for Discovery, Development, and Commercialization of RNAi Therapeutics as Genetic Medicines
Business Wire - Thu Feb 27, 4:00PM CST
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the previously announced alliance with Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY) has closed, following the expiration of the Hart-Scott-Rodino waiting period. The two companies formed the collaboration for the development and commercialization of RNAi therapeutics as genetic medicines on January 11, 2014. In consideration for the rights granted to Genzyme under the alliance and pursuant to the terms of a stock purchase agreement, Genzyme purchased 8,766,338 shares of newly issued Alnylam common stock, representing an approximately 12% ownership position, and paid the company $700.0 million in aggregate cash consideration.
Sanofi/Ardelyx Ink Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 25, 6:00PM CST
Sanofi entered into an agreement with a biopharmaceutical company, Ardelyx Inc.
Which Themes in Biotech Today are Bankable?
Chris Ahlstrand, The Motley Fool - Motley Fool - Tue Feb 25, 5:30PM CST
Sometimes the best way to get started in biotech investing is to analyze specific technologies within the industry. The science and our knowledge of how diseases work is constantly evolving, and every now and then breakthroughs take place which...
Alnylam to Webcast Presentation at Cowen and Company 34th Annual Health Care Conference
Business Wire - Tue Feb 25, 3:00PM CST
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the Cowen and Company 34th Annual Health Care Conference on Tuesday, March 4, 2014 at 11:20 a.m. ET at The Boston Marriott Copley Place in Boston.
Bull of the Day: Alexion Pharma (ALXN) - Bull of the Day
Kevin Cook - Zacks Investment Research - Mon Feb 24, 2:33AM CST
Bull of the Day: Alexion Pharma (ALXN) - Bull of the Day
Alnylam Pharmaceuticals Rises 7.01% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Fri Feb 21, 4:43PM CST
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $84.72 to a high of $90.70. Yesterday, the shares gained 7.0%, which took the trading range above the 3-day high of $85.54 on volume of 1.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Alnylam: Biotech on the Verge of a Breakout
at The Street - Fri Feb 21, 5:00AM CST
Alnylam was rising on unusual volume on Thursday. Here's how to trade it today.
Why Alexion (ALXN) Has A Bright Short-Term Future? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 19, 7:44AM CST
Alexion has seen its Zacks Rank move up from Neutral to Strong Buy over the past four weeks
Alnylam Widens Q4 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 14, 11:00AM CST
Alnylam's fourth quarter 2013 loss of 51 cents per share was wider than the Zacks Consensus Estimate of a loss of 48 cents.
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results and Highlights Recent Period Activities
Business Wire - Thu Feb 13, 3:00PM CST
--- Initiated APOLLO Phase 3 Study with Patisiran (ALN-TTR02) for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis (ATTR) in Patients with Familial Amyloidotic Polyneuropathy (FAP) -
Ligand Beats Q4 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 12, 8:42AM CST
Ligand Pharmaceuticals Inc. (LGND) reported fourth quarter 2013 (ending Dec 2013) adjusted earnings of 28 cents per share, beating the Zacks Consensus Estimate of 20 cents.
3 Trends That Could Define Drug Discovery in 2014
Seth Robey, The Motley Fool - Motley Fool - Wed Feb 12, 7:30AM CST
Last year was undoubtedly remarkable for investors, scientists, and patients as the health care industry soared to new heights. Innovation continued the changing of the guard as biotech supplanted traditional pharmaceutical approaches and biotech's...
Can Alexion Pharmaceuticals Continue to Deliver?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Wed Mar 12, 1:30PM CDT
Successful biotechs are generally expected to reinvest their profits into the development of broad pipelines, but Alexion is following a somewhat different path. While I do not mean to give short shrift to this company's pipeline development...
Marketing Authorization Applications, Quarterly Dividends, Publication of Clinical Trial Data, Acquisitions, and Financial Results - Analyst Notes on Regeneron, Amgen, Sangamo, Alnylam, and Agios
PR Newswire - Tue Mar 11, 8:08AM CDT
Today, Analysts Review released its analysts' notes regarding Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Amgen, Inc. (NASDAQ: AMGN), Sangamo BioSciences, Inc. (NASDAQ: SGMO), Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), and Agios Pharmaceuticals, Inc. (NASDAQ: AGIO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Arrowhead Research Surges as It Advances Its Drug for Hepatitis B into Phase 2
Todd Campbell, The Motley Fool - Motley Fool - Fri Mar 07, 1:30PM CST
Shares in speculative biotechnology company Arrowhead , which was one of 2013's best performing biotechs , jumped nearly 25% following news its lead compound is heading into phase 2 trials. The company won approval from Hong Kong regulators to...
Alnylam Pharmaceuticals acquires Sirna Therapeutics from Merck
M2 - Fri Mar 07, 5:06AM CST
RNAi therapeutics company Alnylam Pharmaceuticals (NasdaqGS:ALNY), based in the US, revealed on Thursday the completion of the acquisition of Sirna Therapeutics in a stock purchase agreement.
Alnylam to Webcast Presentation at Barclays Global Healthcare Conference
Business Wire - Thu Mar 06, 3:00PM CST
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the Barclays Global Healthcare Conference on Thursday, March 13, 2014 at 10:45 a.m. ET at the Loews Miami Hotel in Miami, Florida.
Alnylam Announces Closing of Previously Announced Acquisition of Merck's Sirna Therapeutics Subsidiary
Business Wire - Thu Mar 06, 7:01AM CST
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the previously announced acquisition of Merck's wholly owned subsidiary Sirna Therapeutics, Inc. ("Sirna Therapeutics" or "Sirna") has closed, following the expiration of the Hart-Scott-Rodino waiting period. On January 10, 2014, Alnylam entered into a stock purchase agreement with Merck pursuant to which Alnylam agreed to purchase from Merck all of Merck's rights, title, and interest in and to all of the outstanding shares of common stock of Sirna Therapeutics. In consideration for the Sirna common stock, Alnylam paid Merck $25.0 million in cash. In addition, Alnylam agreed to issue to Merck 2,520,044 shares of Alnylam common stock, having a value of $150.0 million as calculated under the terms of the stock purchase agreement on the date of execution, and representing an approximately 3% ownership position in Alnylam's outstanding common stock. Alnylam issued 85% of the shares at the closing and will issue the remainder of shares upon the completion of certain technology transfer activities pursuant to the terms of the stock purchase agreement.
Are These Biotechs Part of Your Portfolio? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 9:52AM CST
The biotech sector holds great promise and is expected to grow at a rapid pace.
Alnylam Announces Closing of Previously Announced Alliance with Genzyme for Discovery, Development, and Commercialization of RNAi Therapeutics as Genetic Medicines
Business Wire - Thu Feb 27, 4:00PM CST
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the previously announced alliance with Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY) has closed, following the expiration of the Hart-Scott-Rodino waiting period. The two companies formed the collaboration for the development and commercialization of RNAi therapeutics as genetic medicines on January 11, 2014. In consideration for the rights granted to Genzyme under the alliance and pursuant to the terms of a stock purchase agreement, Genzyme purchased 8,766,338 shares of newly issued Alnylam common stock, representing an approximately 12% ownership position, and paid the company $700.0 million in aggregate cash consideration.
Sanofi/Ardelyx Ink Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 25, 6:00PM CST
Sanofi entered into an agreement with a biopharmaceutical company, Ardelyx Inc.
Which Themes in Biotech Today are Bankable?
Chris Ahlstrand, The Motley Fool - Motley Fool - Tue Feb 25, 5:30PM CST
Sometimes the best way to get started in biotech investing is to analyze specific technologies within the industry. The science and our knowledge of how diseases work is constantly evolving, and every now and then breakthroughs take place which...
Alnylam to Webcast Presentation at Cowen and Company 34th Annual Health Care Conference
Business Wire - Tue Feb 25, 3:00PM CST
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the Cowen and Company 34th Annual Health Care Conference on Tuesday, March 4, 2014 at 11:20 a.m. ET at The Boston Marriott Copley Place in Boston.
Bull of the Day: Alexion Pharma (ALXN) - Bull of the Day
Kevin Cook - Zacks Investment Research - Mon Feb 24, 2:33AM CST
Bull of the Day: Alexion Pharma (ALXN) - Bull of the Day
Alnylam Pharmaceuticals Rises 7.01% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Fri Feb 21, 4:43PM CST
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $84.72 to a high of $90.70. Yesterday, the shares gained 7.0%, which took the trading range above the 3-day high of $85.54 on volume of 1.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Alnylam: Biotech on the Verge of a Breakout
at The Street - Fri Feb 21, 5:00AM CST
Alnylam was rising on unusual volume on Thursday. Here's how to trade it today.
Why Alexion (ALXN) Has A Bright Short-Term Future? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 19, 7:44AM CST
Alexion has seen its Zacks Rank move up from Neutral to Strong Buy over the past four weeks
Alnylam Widens Q4 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 14, 11:00AM CST
Alnylam's fourth quarter 2013 loss of 51 cents per share was wider than the Zacks Consensus Estimate of a loss of 48 cents.
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results and Highlights Recent Period Activities
Business Wire - Thu Feb 13, 3:00PM CST
--- Initiated APOLLO Phase 3 Study with Patisiran (ALN-TTR02) for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis (ATTR) in Patients with Familial Amyloidotic Polyneuropathy (FAP) -
Ligand Beats Q4 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 12, 8:42AM CST
Ligand Pharmaceuticals Inc. (LGND) reported fourth quarter 2013 (ending Dec 2013) adjusted earnings of 28 cents per share, beating the Zacks Consensus Estimate of 20 cents.
3 Trends That Could Define Drug Discovery in 2014
Seth Robey, The Motley Fool - Motley Fool - Wed Feb 12, 7:30AM CST
Last year was undoubtedly remarkable for investors, scientists, and patients as the health care industry soared to new heights. Innovation continued the changing of the guard as biotech supplanted traditional pharmaceutical approaches and biotech's...
